Multiple Myeloma Response Criteria (IMWG)
ورودیهای بالینی بیمار
حداقل ۰ — حداکثر ۱۰۰ • واحد: %
حداقل ۰.۰۱ — حداکثر ۱۰۰۰
حداقل ۰ — حداکثر ۱۰۰ • واحد: %
حداقل ۰ — حداکثر ۱۰۰۰۰ • واحد: mg
حداقل ۰ — حداکثر ۱۰۰ • واحد: %
پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.
- Stringent Complete Response (sCR)1–1
- Complete Response (CR)2–2
- Very Good Partial Response (VGPR)3–3
- Partial Response (PR)4–4
The Multiple Myeloma Response Criteria (IMWG) calculates determining thromboembolic risk, heparin-induced thrombocytopenia probability, and bleeding diathesis. Key inputs include serum immunofixation. Scores guide initiating targeted anticoagulation therapy, platelet monitoring, or hematology specialist referral. This standardized assessment improves clinical decision safety and bedside patient management.
Clinical Guidelines & Evidence
Evaluates disease response in multiple myeloma according to International Myeloma Working Group (IMWG) criteria including Complete Response, Partial Response, and Progressive Disease categories.
Clinical Indication
The Multiple Myeloma Response Criteria (IMWG) is indicated for bedside clinical practice to support Evaluates disease response in multiple myeloma according to International Myeloma Working Group (IMWG) criteria including Complete Response, Partial Response, and Progressive Disease categories.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.
Target Population
Target population comprises Patients presenting with coagulopathy, thrombocytopenia, venous thromboembolism (DVT/PE), or hematologic neoplasms. Clinical application is indicated across Hematology-oncology services, bone marrow transplant units, anticoagulation clinics, and acute medical wards.
Limitations & Contraindications
Severe thrombocytopenia with concomitant microvascular thrombosis (TTP, HIT, DIC) represents a medical emergency requiring rapid intervention.
Clinical Pearls & Action Plan
Detailed history of heparin exposure, platelet count kinetics, and comprehensive coagulation profiles are vital in consumptive coagulopathies. Guideline pearl: Integration with survival outcomes guides treatment decisions.
IMWG Response Assessment: Based on immunofixation results, bone marrow plasma cell percentage, M protein levels, soft tissue plasmacytomas, free light chain ratio, and clonal cell presence to determine response category (sCR, CR, VGPR, PR, SD, or PD)
Input Parameters
| Name | Type | Required | Description |
|---|---|---|---|
| serum_immunofixation | string | Yes | Serum immunofixation result |
| urine_immunofixation | string | Yes | Urine immunofixation result |
| bone_marrow_plasma_cells | float | Yes | Percentage of plasma cells in bone marrow(%) |
| soft_tissue_plasmacytomas | string | Yes | Presence of soft tissue plasmacytomas |
| free_light_chain_ratio | float | No | Serum free light chain ratio (involved/uninvolved) |
| clonal_cells_bone_marrow | string | No | Clonal cells in bone marrow by immunohistochemistry/immunofluorescence |
| serum_m_protein_reduction | float | No | Percentage reduction in serum M protein from baseline(%) |
| urine_m_protein_24h | float | No | 24-hour urine M protein level(mg) |
| serum_electrophoresis_detectable | string | No | M component detectable by serum electrophoresis |
| plasmacytoma_reduction | float | No | Percentage reduction in soft tissue plasmacytoma size(%) |
Score Interpretation & Guidance
| Range | Stage | Description |
|---|---|---|
| 1–1 | Stringent Complete Response (sCR) | Best possible response |
| 2–2 | Complete Response (CR) | Complete response |
| 3–3 | Very Good Partial Response (VGPR) | Very good partial response |
| 4–4 | Partial Response (PR) | Partial response |
| 5–5 | Stable Disease (SD) | Stable disease |
| 6–6 | Progressive Disease (PD) | Disease progression |
Evidence-Based References (EBM)
- Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):e328-e346. doi: 10.1016/S1470-2045(16)30206-6.DOI: 10.1016/S1470-2045(16)30206-6
- Durie BG, Harousseau JL, Miguel JS, Bladé J, Barlogie B, Anderson K, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20(9):1467-73. doi: 10.1038/sj.leu.2404284.DOI: 10.1038/sj.leu.2404284
- Rajkumar SV, Harousseau JL, Durie B, Anderson KC, Dimopoulos M, Kyle R, et al. Consensus guidelines for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood. 2011;117(18):4691-5. doi: 10.1182/blood-2010-10-299487.DOI: 10.1182/blood-2010-10-299487